People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cadrenal Therapeutics, Inc. | — | Biotechnology | Series A | $21.7M | $11.4M | 2024 |
Steven W. Zelenkofske at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven W. Zelenkofske on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Murphy | 1 | 17 |
| Matthew Szot | 1 | 4 |
| Matthew K Szot | 1 | 3 |
| Douglas Losordo | 1 | 2 |
| LEE S. GOLDEN | 1 | 2 |
| GLYNN WILSON | 1 | 2 |
| STEVEN J. ZELENKOFSKE | 1 | 1 |
| Jeff W. Cole | 1 | 1 |
| Glynn W. Wilson | 1 | 1 |
| Douglas W. Losordo | 1 | 1 |
| Quang Pham | 1 | 1 |
| Robert W. Lisicki | 1 | 1 |
| STEVEN ZELENKOFSKE | 1 | 1 |
| JOHN R. MURPHY | 1 | 1 |
| JEFFREY K. COLE | 1 | 1 |
| QUANG X. PHAM | 1 | 1 |
| JAMES J. FERGUSON | 1 | 1 |
| GLYNN J. WILSON | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.